 |
| 18-Apr-13 | Reiterated |
Argus |
Buy |
$80 → $96 |
|
| 15-Apr-13 | Reiterated |
Barclays |
Overweight |
$85 → $95 |
|
| 12-Apr-13 | Reiterated |
Deutsche Bank |
Buy |
$82 → $87 |
|
| 26-Mar-13 | Reiterated |
UBS |
Buy |
$81 → $87 |
|
| 11-Jan-13 | Reiterated |
UBS |
Buy |
$76 → $78 |
|
| 04-Jan-13 | Upgrade |
Deutsche Bank |
Hold → Buy |
$75 → $82 |
|
| 20-Nov-12 | Initiated |
Stifel Nicolaus |
Hold |
|
|
| 18-Jul-12 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$65 → $71 |
|
| 18-Apr-12 | Reiterated |
UBS |
Buy |
$71 → $70 |
|
| 12-Dec-11 | Reiterated |
UBS |
Buy |
$72 → $69 |
|
| 17-Oct-11 | Reiterated |
UBS |
Buy |
$74 → $72 |
|
| 24-Aug-11 | Reiterated |
Morgan Keegan |
Mkt Perform |
$70 → $68 |
|
| 29-Apr-11 | Reiterated |
UBS |
Buy |
$67 → $72 |
|
| 26-Jan-11 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$60 → $58 |
|
| 18-Jan-11 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$62 → $60 |
|
| 14-Jan-11 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$62 → $60 |
|
| 21-Jul-10 | Reiterated |
UBS |
Buy |
$75 → $69 |
|
| 21-Jul-10 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$63 → $62 |
|
| 01-Jul-10 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 15-Jul-09 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$54 → $60 |
|
|
|
| 24-May-13 06:03PM | Final Glance: Pharmaceuticals companies AP |
| 06:03PM | Final Glance: Medical Devices companies AP |
| 04:12PM | Rivaroxaban Gains Approval In Europe For ACS Indication at Forbes |
| 03:53PM | [video] Summer Investing: Advice From the Pros at CNBC |
| 03:00PM | Is Blue-Chip Dividend Investing Only For Rich People? at Seeking Alpha |
| 02:31PM | Analysts: Johnson & Johnson Drug Revenue Could Double and 3 More Research Notes to Read at Wall St. Cheat Sheet |
| 01:17PM | Midday Glance: Pharmaceuticals companies AP |
| 01:17PM | Midday Glance: Medical Devices companies AP |
| 01:00PM | Dow Today: Johnson & Johnson (JNJ) Lower at TheStreet |
| 10:48AM | Bill Ackman Strikes Again: P&Gs McDonald Out, Lafley In The Daily Ticker |
| 10:33AM | Early Glance: Pharmaceuticals companies AP |
| 10:33AM | Early Glance: Medical Devices companies AP |
| 10:25AM | Bernankes Testimony and Market Uncertainty: Week in Review at Wall St. Cheat Sheet |
| 09:19AM | New Stock Coverage: Look at LeapFrog Jump at Minyanville |
| 08:58AM | Recession Is Coming at Seeking Alpha |
| 07:23AM | Ackman wins, P&G dumps CEO at CNNMoney.com |
| 23-May-13 06:25PM | Alkermes Earnings Beat Estimates, But Outlook Unclear at Investor's Business Daily |
| 06:04PM | Final Glance: Pharmaceuticals companies AP |
| 06:04PM | Final Glance: Medical Devices companies AP |
| 05:41PM | [$$] Big Profits From Bad Backs at Barrons.com |
| 05:25PM | J&J Drugs to Create Next Wave of Growth, Duato Says at Bloomberg |
| 04:42PM | News Summary: J&J predicts surge of new medicines AP |
| 04:08PM | More Danger Signs for the Market at Motley Fool |
| 03:59PM | J&J expects 10-plus new drug applications by 2017 AP |
| 03:48PM | Follow The 'Smart Money' And Buy Johnson & Johnson In The Next Pullback at Seeking Alpha |
| 02:03PM | How Dividends Change the Game for Cisco Shareholders at Motley Fool |
| 01:52PM | Alkermes Stock Seesaws After Q4 Beat, Guidance Miss at Investor's Business Daily |
| 01:49PM | Johnson & Johnson Is Going Big With New Meds at Wall St. Cheat Sheet |
| 01:47PM | Midday Glance: Pharmaceuticals companies AP |
| 01:47PM | Midday Glance: Medical Devices companies AP |
| 01:33PM | Johnson & Johnson Is Reinventing The Party Drug Ketamine To Treat Depression at Forbes |
| 01:25PM | Alkermes Reports Earnings for Q4 Zacks |
| 12:44PM | Alkermes posts 4Q profit as royalty payments rise AP |
| 11:20AM | Socially Minded Seniors Keep Co-Op Spirit Alive In Cambridge at Forbes |
| 11:01AM | Johnson & Johnson to seek OK for 10 new treatments by 2017 at MarketWatch |
| 10:46AM | Early Glance: Pharmaceuticals companies AP |
| 10:46AM | Early Glance: Medical Devices companies AP |
| 10:22AM | Google Saves HPs Quarter and 3 More Hot Stocks at Wall St. Cheat Sheet |
| 09:46AM | J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizer at Forbes |
| 09:25AM | New Stock Coverage: Can Johnson & Johnson Be Market's Band-Aid? at Minyanville |
| 08:31AM | J&J forecasts 10 new drug applications by 2017 AP |
| 08:30AM | J&J plans filing on more than 10 new drugs by 2017 at Reuters |
| 08:30AM | Workday's Loss Narrows in 1Q Zacks |
| 07:56AM | Johnson & Johnson plans on more than 10 drugs filed by 2017 at Reuters |
| 07:39AM | J&J Sees 10 Products Submitted For Approval by 2017 at Bloomberg |
| 07:36AM | InPlay: Johnson & Johnson pharmaceuticals segment poised to continue driving growth with more than 10 potential new product filings by 2017 Briefing.com |
| 07:31AM | Janssen expects to have more than 25 brand line extensions by 2017 at theflyonthewall.com |
| 07:30AM | Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017 PR Newswire |
| 06:30AM | Johnson & Johnson: At The Crossroads - Part IV - One Road To Higher Profit Growth Rates at Seeking Alpha |
| 06:29AM | Johnson & Johnson coverage assumed with an Underperform at Credit Suisse theflyonthewall.com |
| 22-May-13 06:35PM | Can Financial Innovation Unlock a Cure for Cancer? at Motley Fool |
| 06:08PM | Final Glance: Medical Devices companies AP |
| 06:08PM | Final Glance: Pharmaceuticals companies AP |
| 03:55PM | Gilead's Sofosbuvir under European Review Zacks |
| 03:20PM | A Moderate-Risk, High-Reward Dividend Play at Seeking Alpha |
| 02:49PM | Watch This HCV Player at Motley Fool |
| 02:22PM | Exxon Mobil Gives $500K to Oklahoma Relief and 2 Other Dow Movers to Watch at Wall St. Cheat Sheet |
| 01:48PM | Apple Still Hedge Funds' Most Popular Stock, But AIG Matters More at Barrons.com |
| 01:44PM | Final Trade: Your First Move for Thursday, May 23 at CNBC |
| 01:30PM | Is There Growth Left in Massive Drug Stocks? at Motley Fool |
| 01:17PM | Midday Glance: Pharmaceuticals companies AP |
| 01:17PM | Midday Glance: Medical Devices companies AP |
| 01:16PM | Midday Movers: GE, OPEN, CTRX & More at CNBC |
| 12:59PM | Equities Can Rise Another 5%-10% On Bernanke's Comments at Seeking Alpha |
| 11:45AM | Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says at Bloomberg |
| 11:42AM | [video] Benefiting From the Rotation To Cyclicals at TheStreet |
| 11:35AM | Medtronic Still Reporting Weak Growth, But A Relatively Rare Bargain at Investopedia |
| 11:00AM | Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrow at TheStreet |
| 10:51AM | Early Glance: Pharmaceuticals companies AP |
| 10:51AM | Early Glance: Medical Devices companies AP |
| 10:39AM | Swiss Billionaires Buy Merck Geneva Building for Biotech Campus at Bloomberg |
| 10:00AM | 5 Stocks Going Ex-Dividend Tomorrow: SMG, FMER, AIZ, KEY, JNJ at TheStreet |
| 08:50AM | Allocate Assets to Buy-Rated Dow Stocks TheStreet |
| 06:40AM | Stock Market News for May 22, 2013 Zacks |
| 05:32AM | The Long Case For 3M at Seeking Alpha |
| 21-May-13 08:50PM | Final Glance: Pharmaceuticals companies AP |
| 08:50PM | Final Glance: Medical Devices companies AP |
| 07:44PM | [video] Will the Bulls Keep Running Into 2015? at CNBC |
| 06:30PM | The Surprising Link Between ADHD and Obesity at Motley Fool |
| 05:46PM | Pfizer Stock Checkup for May at Motley Fool |
| 05:41PM | JPMorgan Directors Glance: How shareholders voted AP |
| 03:32PM | J&J, Up 26% YTD, Gets After Image Problems YCharts |
| 03:28PM | JPMorgan Directors Glance: How shareholders voted AP |
| 03:05PM | Roche, Reloaded at Investopedia |
| 02:00PM | Harvards Largest Gift Doubles With Second Wyss Donation at Bloomberg |
| 01:16PM | Midday Glance: Pharmaceuticals companies AP |
| 01:16PM | Midday Glance: Medical Devices companies AP |
| 10:58AM | Jim Cramer: Buy Johnson & Johnson, Buy CarMax, Buy These 3 Stocks at Wall St. Cheat Sheet |
| 10:50AM | JNJ's Simponi Label Expanded Zacks |
| 10:36AM | Early Glance: Pharmaceuticals companies AP |
| 10:36AM | Early Glance: Medical Devices companies AP |
| 09:42AM | Long-Term Biotech: 3 Names To Discover Now at Seeking Alpha |
| 09:27AM | Is There a Pill For That? Forest Labs Iffy Pipeline YCharts |
| 08:59AM | Medtronics Heart Rhythm Devices Show Signs of Growth at Bloomberg |
| 06:13AM | [$$] Dividend Stocks, the New Nifty 50? at Barrons.com |
| 02:06AM | Johnson & Johnson Stock Checkup for May at Motley Fool |
| 02:05AM | Cordis Showcases Cardiovascular Innovations at EuroPCR 2013 Business Wire |
| 20-May-13 08:45PM | The Case for Big Bank Stocks in Your Retirement Account at Motley Fool |
| 06:09PM | 2013's Top 5 Companies for the Ordinary Investor at Motley Fool |
| 06:05PM | Final Glance: Pharmaceuticals companies AP |
|
|
| Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers products used in the baby care, skin care, oral care, wound care, and women's health fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON'S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, DABAO, VENDME, LISTERINE, REMBRANDT, REACH, BAND-AID, NEOSPORIN, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products directly, as well as through surgical supply and other distributors to wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| CULLEN JAMES | Director | May 07 | Sale | 85.40 | 4,929 | 420,937 | 3,849 | May 08 03:31 PM | | Gorsky Alex | Chairman, CEO | Feb 08 | Option Exercise | 0.00 | 9,981 | 0 | 74,115 | Feb 12 06:27 PM | | Stoffels Paulus | Chief Scientific Officer | Feb 08 | Option Exercise | 0.00 | 18,391 | 0 | 18,490 | Feb 12 06:25 PM | | Ullmann Michael H | VP, General Counsel | Feb 08 | Option Exercise | 0.00 | 8,943 | 0 | 54,706 | Feb 12 06:23 PM | | WELDON WILLIAM C | Former Chairman of the Board | Feb 08 | Option Exercise | 0.00 | 48,906 | 0 | 329,780 | Feb 12 06:19 PM | | Caruso Dominic J | Chief Financial Officer | Feb 08 | Option Exercise | 0.00 | 9,981 | 0 | 57,891 | Feb 12 06:16 PM | | COSGROVE STEPHEN J | Corporate Controller | Feb 08 | Option Exercise | 0.00 | 2,345 | 0 | 85,175 | Feb 22 06:45 PM | | SATCHER DAVID | Director | Feb 05 | Option Exercise | 52.20 | 6,300 | 328,860 | 19,830 | Feb 07 04:54 PM | | Ullmann Michael H | VP, General Counsel | Jan 25 | Option Exercise | 52.20 | 1,915 | 99,963 | 47,115 | Jan 29 04:25 PM | | WELDON WILLIAM C | Director | Dec 13 | Option Exercise | 66.18 | 1,510 | 99,932 | 408,874 | Dec 17 11:21 AM | | LINDQUIST SUSAN L | Director | Dec 07 | Option Exercise | 53.93 | 7,600 | 409,868 | 22,205 | Dec 10 06:10 PM | | LINDQUIST SUSAN L | Director | Dec 07 | Sale | 70.02 | 7,600 | 532,152 | 14,605 | Dec 10 06:10 PM | | CULLEN JAMES | Director | Nov 12 | Option Exercise | 52.20 | 6,300 | 328,860 | 14,704 | Nov 14 11:10 AM | | CULLEN JAMES | Director | Nov 12 | Sale | 69.70 | 13,900 | 968,830 | 8,404 | Nov 14 11:10 AM | | MULLIN LEO F | Director | Oct 23 | Option Exercise | 52.20 | 6,300 | 328,860 | 27,733 | Oct 25 03:02 PM | | Caruso Dominic J | Chief Financial Officer | Oct 19 | Option Exercise | 52.20 | 20,400 | 1,064,880 | 68,258 | Oct 22 04:07 PM | | Caruso Dominic J | Chief Financial Officer | Oct 19 | Sale | 71.95 | 20,400 | 1,467,780 | 47,858 | Oct 22 04:07 PM | | WELDON WILLIAM C | Chairman/CEO | Sep 07 | Option Exercise | 53.93 | 323,150 | 17,427,480 | 730,514 | Sep 11 06:05 PM | | COSGROVE STEPHEN J | Corporate Controller | Sep 07 | Option Exercise | 52.20 | 23,085 | 1,205,037 | 102,915 | Sep 11 06:09 PM | | COSGROVE STEPHEN J | Corporate Controller | Sep 07 | Sale | 67.78 | 20,085 | 1,361,361 | 82,830 | Sep 11 06:09 PM | | WELDON WILLIAM C | Chairman/CEO | Sep 07 | Sale | 67.66 | 323,150 | 21,864,329 | 407,364 | Sep 11 06:05 PM | | COSGROVE STEPHEN J | Corporate Controller | Jul 20 | Option Exercise | 52.20 | 1,915 | 99,963 | 81,267 | Jul 23 01:17 PM | | COLEMAN MARY SUE | Director | Jul 19 | Option Exercise | 53.93 | 7,600 | 409,868 | 21,952 | Jul 20 05:37 PM |
|
|
|
|
|
|
